Prostate Cancer最新文献_第6页

Triptorelin in the Relief of Lower Urinary Tract Symptoms in Advanced Prostate Cancer Patients: The RESULT Study. 雷普妥林缓解晚期前列腺癌患者下尿路症状的结果研究

IF 4.2

Prostate Cancer Pub Date : 2015-01-01 Epub Date: 2015-01-28 DOI: 10.1155/2015/978194

Alexandre Peltier, Fouad Aoun, Vincent De Ruyter, Patrick Cabri, Roland Van Velthoven

{"title":"Triptorelin in the Relief of Lower Urinary Tract Symptoms in Advanced Prostate Cancer Patients: The RESULT Study.","authors":"Alexandre Peltier, Fouad Aoun, Vincent De Ruyter, Patrick Cabri, Roland Van Velthoven","doi":"10.1155/2015/978194","DOIUrl":"https://doi.org/10.1155/2015/978194","url":null,"abstract":"This prospective, noninterventional, open-label, multicentre, Belgian study assessed the prevalence of moderate to severe lower urinary tract symptoms (LUTS) in patients with locally advanced or metastatic prostate cancer scheduled to receive triptorelin therapy and its effects on LUTS were evaluated focusing on symptom relief and changes in quality of life (QOL) related to urinary symptoms (November 2006 to May 2010). Inclusion criteria were age >18 years, histologically confirmed advanced or metastatic prostate cancer, and life expectancy ≥12 months. Exclusion criteria were treatment with any LHRH analogue within the last 6 months or any other investigational agent within the last 3 months before study entry. Patients who received one or more triptorelin doses and had one or more efficacy assessments were evaluated. In total, 325 patients were included with a median age of 74 years (50 to 95 years). Mean age at first diagnosis was 73 ± 8 years. Moderate (IPSS 8-19) to severe (IPSS ≥ 20) LUTS were observed in 62% of patients. Triptorelin reduced LUTS severity. This improvement was perceived within the first 24 weeks of treatment and was maintained after 48 weeks. A decrease in PSA level was also observed. ","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2015 ","pages":"978194"},"PeriodicalIF":4.2,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/978194","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33065032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 11

Current Patterns of Management of Advanced Prostate Cancer in Routine Clinical Practice in Spain. 西班牙晚期前列腺癌常规临床实践的当前管理模式。

IF 4.2

Prostate Cancer Pub Date : 2015-01-01 Epub Date: 2015-07-13 DOI: 10.1155/2015/186740

Maria José Ribal, Juan Ignacio Martínez-Salamanca, Camilo García Freire

{"title":"Current Patterns of Management of Advanced Prostate Cancer in Routine Clinical Practice in Spain.","authors":"Maria José Ribal, Juan Ignacio Martínez-Salamanca, Camilo García Freire","doi":"10.1155/2015/186740","DOIUrl":"https://doi.org/10.1155/2015/186740","url":null,"abstract":"Objective. To describe urologists' practice patterns when managing patients with advanced prostate cancer (PCa) in Spain. Methods. This was an observational study conducted by 120 urologists using retrospective data of advanced PCa patients attending hospitals and outpatient centers. Results. Urologists evaluated a total of 375 patients (mean age: 75 years; ECOG 0-1: 77%; mean serum PSA levels at study entry: 50.5 ng/Ml). Approximately 50% of patients had bone metastases, and 60.6% experienced pain as the main symptom of progressive disease. Primary androgen deprivation therapy (ADT) use was 99.7%, with continuous ADT as the dominant strategy (91.9%). After failure of initial ADT, antiandrogen withdrawal was the next method most commonly used in 57% of patients. Choice of secondary hormonal treatment was made mostly by urologists (96%), who continued to monitor patients. Patient follow-up after chemotherapy and supportive care were mainly done in urology units, although responsibility was shared with medical oncologists and radiologists. Conclusion. The urologists' attitudes towards management of PCa in the routine practice in Spain show the urologist as an integral component even when patients progress to advanced stages of the disease. ","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2015 ","pages":"186740"},"PeriodicalIF":4.2,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/186740","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33899944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

Cellular Plasticity in Prostate Cancer Bone Metastasis. 前列腺癌骨转移中的细胞可塑性

IF 4.2

Prostate Cancer Pub Date : 2015-01-01 Epub Date: 2015-06-03 DOI: 10.1155/2015/651580

Dima Y Jadaan, Mutaz M Jadaan, John P McCabe

{"title":"Cellular Plasticity in Prostate Cancer Bone Metastasis.","authors":"Dima Y Jadaan, Mutaz M Jadaan, John P McCabe","doi":"10.1155/2015/651580","DOIUrl":"https://doi.org/10.1155/2015/651580","url":null,"abstract":"Purpose. Experimental data suggest that tumour cells can reversibly transition between epithelial and mesenchymal states (EMT and MET), a phenomenon known as cellular plasticity. The aim of this review was to appraise the clinical evidence for the role of cellular plasticity in prostate cancer (PC) bone metastasis. Methods. An electronic search was performed using PubMed for studies that have examined the differential expression of epithelial, mesenchymal, and stem cell markers in human PC bone metastasis tissues. Results. The review included nineteen studies. More than 60% of the studies used ≤20 bone metastasis samples, and there were several sources of heterogeneity between studies. Overall, most stem cell markers analysed, except for CXCR4, were positively expressed in bone metastasis tissues, while the expression of EMT and MET markers was heterogeneous between and within samples. Several EMT and stemness markers that are involved in osteomimicry, such as Notch, Met receptor, and Wnt/β pathway, were highly expressed in bone metastases. Conclusions. Clinical findings support the role of cellular plasticity in PC bone metastasis and suggest that epithelial and mesenchymal states cannot be taken in isolation when targeting PC bone metastasis. The paper also highlights several challenges in the clinical detection of cellular plasticity. ","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2015 ","pages":"651580"},"PeriodicalIF":4.2,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/651580","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33880429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 24

Atypical Small Acinar Proliferation: Repeat Biopsy and Detection of High Grade Prostate Cancer. 非典型小腺泡增生:重复活检和高级别前列腺癌的检测。

IF 4.2

Prostate Cancer Pub Date : 2015-01-01 Epub Date: 2015-09-14 DOI: 10.1155/2015/810159

Andrew Leone, Katherine Rotker, Christi Butler, Anthony Mega, Jianhong Li, Ali Amin, Stephen F Schiff, Gyan Pareek, Dragan Golijanin, Joseph F Renzulli

{"title":"Atypical Small Acinar Proliferation: Repeat Biopsy and Detection of High Grade Prostate Cancer.","authors":"Andrew Leone, Katherine Rotker, Christi Butler, Anthony Mega, Jianhong Li, Ali Amin, Stephen F Schiff, Gyan Pareek, Dragan Golijanin, Joseph F Renzulli","doi":"10.1155/2015/810159","DOIUrl":"https://doi.org/10.1155/2015/810159","url":null,"abstract":"Purpose. Atypical small acinar proliferation (ASAP) is diagnosed in 1-2% of prostate biopsies. 30-40% of patients with ASAP may be diagnosed with prostate cancer (PCa) on repeat biopsy. Our objective was to examine the association between ASAP and subsequent diagnosis of intermediate/high risk PCa. Materials and Methods. Ninety-six patients who underwent prostate biopsy from 2000 to 2013 and were diagnosed with ASAP were identified. Clinicopathologic features were analyzed. Comparison was made between those with subsequent PCa on repeat biopsy and those with benign repeat pathology. Results. 56/96 (58%) patients had a repeat biopsy. 22/56 (39%) were subsequently diagnosed with PCa. There was no significant difference in patients' characteristics. Presence of HGPIN on initial biopsy was associated with a benign repeat biopsy (68% versus 23%). 17/22 (77%) had Gleason grade (GG) 3+3 disease and only 5/22 (23%) had GG 3+4 disease. Conclusions. 22/56 patients (39%) of patients who underwent a subsequent prostate biopsy following a diagnosis of ASAP were found to have PCa. 77% of these men were diagnosed with GG 3+3 PCa. Only 23% were found to have intermediate risk PCa and no high risk PCa was identified. Immediate repeat prostate biopsy in patients diagnosed with ASAP may be safely delayed. A multi-institutional cohort is being analyzed. ","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2015 ","pages":"810159"},"PeriodicalIF":4.2,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/810159","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34140874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 14

Phase I Study of Anti-CD3 x Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer Patients. 抗 CD3 x 抗 Her2 双特异性抗体治疗转移性阉割耐药前列腺癌患者的 I 期研究。

IF 4.2

Prostate Cancer Pub Date : 2015-01-01 Epub Date: 2015-02-23 DOI: 10.1155/2015/285193

Ulka Vaishampayan, Archana Thakur, Ritesh Rathore, Nicola Kouttab, Lawrence G Lum

{"title":"Phase I Study of Anti-CD3 x Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer Patients.","authors":"Ulka Vaishampayan, Archana Thakur, Ritesh Rathore, Nicola Kouttab, Lawrence G Lum","doi":"10.1155/2015/285193","DOIUrl":"10.1155/2015/285193","url":null,"abstract":"Background. New nontoxic targeted approaches are needed for patients with castrate resistant prostate cancer (CRPC). Our preclinical studies show that activated T cells (ATC) armed with anti-CD3 x anti-Her2 bispecific antibody (Her2Bi) kill prostate cancer cells lines, induce a Th1 cytokine pattern upon engagement of tumor cells, prevent the development of prostate tumors, and retard tumor growth in immunodeficient mice. These studies provided strong rationale for our phase I dose-escalation pilot study to test ATC armed with Her2Bi (aATC) for safety in men with CRPC. Methods. Seven of 8 men with CRPC were evaluable after receiving two infusions per week for 4 weeks. The men received 2.5, 5 or 10 × 10(9) aATC per infusion with low dose interleukin-2 and granulocyte-macrophage colony stimulating factor. Results. There were no dose limiting toxicities, and there was 1 partial responder and 3 of 7 patients had significant decreases in their PSA levels and pain scores. Immune evaluations of peripheral blood mononuclear cells in 2 patients before and after immunotherapy showed increases in IFN-γ EliSpot responses and Th1 serum cytokines. Conclusions. These results provide a strong rationale for developing phase II trials to determine whether aATC are effective for treating CRPC. ","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2015 ","pages":"285193"},"PeriodicalIF":4.2,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4352947/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33155792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of transperineal mapping biopsy results with whole-mount radical prostatectomy pathology in patients with localized prostate cancer. 局部前列腺癌经会阴穿刺活检结果与全支架根治性前列腺切除术病理比较。

IF 4.2

Prostate Cancer Pub Date : 2014-01-01 Epub Date: 2014-05-11 DOI: 10.1155/2014/781438

Darren J Katz, Rodrigo Pinochet, Kyle A Richards, Guilherme Godoy, Kazuma Udo, Lucas Nogueira, Angel M Cronin, Samson W Fine, Peter T Scardino, Jonathon A Coleman

{"title":"Comparison of transperineal mapping biopsy results with whole-mount radical prostatectomy pathology in patients with localized prostate cancer.","authors":"Darren J Katz, Rodrigo Pinochet, Kyle A Richards, Guilherme Godoy, Kazuma Udo, Lucas Nogueira, Angel M Cronin, Samson W Fine, Peter T Scardino, Jonathon A Coleman","doi":"10.1155/2014/781438","DOIUrl":"https://doi.org/10.1155/2014/781438","url":null,"abstract":"Objective. We sought to evaluate the accuracy of transperineal mapping biopsy (TMB) by comparing it to the pathology specimen of patients who underwent radical prostatectomy (RP) for localized prostate cancer. Methods. From March 2007 to September 2009, 78 men at a single center underwent TMB; 17 of 78 subsequently underwent RP. TMB cores were grouped into four quadrants and matched to data from RP whole-mount slides. Gleason score, tumor location and volume, cross-sectional area, and maximal diameter were measured; sensitivity and specificity were assessed. Results. For the 17 patients who underwent RP, TMB revealed 12 (71%) had biopsy Gleason grades ≥ 3 + 4 and 13 (76%) had bilateral disease. RP specimens showed 14 (82%) had Gleason scores ≥ 3 + 4 and 13 (76%) had bilateral disease. Sensitivity and specificity of TMB for prostate cancer detection were 86% (95% confidence interval [CI] 72%-94%) and 83% (95% CI 62%-95%), respectively. Four quadrants negative for cancer on TMB were positive on prostatectomy, and six positive on TMB were negative on prostatectomy. Conclusion. TMB is a highly invasive procedure that can accurately detect and localize prostate cancer. These findings help establish baseline performance characteristics for TMB and its utility for organ-sparing strategies. ","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2014 ","pages":"781438"},"PeriodicalIF":4.2,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2014/781438","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32399259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 10

Primary Zonal High Intensity Focused Ultrasound for Prostate Cancer: Results of a Prospective Phase IIa Feasibility Study. 治疗前列腺癌的原发区域高强度聚焦超声：前瞻性 IIa 期可行性研究结果。

IF 4.2

Prostate Cancer Pub Date : 2014-01-01 Epub Date: 2014-01-23 DOI: 10.1155/2014/756189

Roland Van Velthoven, Fouad Aoun, Ksenija Limani, Krishna Narahari, Marc Lemort, Alexandre Peltier

{"title":"Primary Zonal High Intensity Focused Ultrasound for Prostate Cancer: Results of a Prospective Phase IIa Feasibility Study.","authors":"Roland Van Velthoven, Fouad Aoun, Ksenija Limani, Krishna Narahari, Marc Lemort, Alexandre Peltier","doi":"10.1155/2014/756189","DOIUrl":"10.1155/2014/756189","url":null,"abstract":"Objectives: To present the results of a prospective phase IIa study assessing the role of primary zonal High Intensity Focused Ultrasound (HIFU) for prostate cancer treatment.Methods: 31 consecutive patients with unilateral organ confined prostate cancer primarily treated by zonal HIFU (from February 2007 to June 2011) were recruited into a single centre prospective phase IIa feasibility study. Complications were prospectively recorded and graded according to the Clavien-Dindo score. Postoperatively, patients were followed with serial serum PSA determinations and digital rectal examinations. An individual PSA nadir was identified in each patient. Followup also included whole gland biopsies performed in the event of a PSA rising>2.0 ng/mL above nadir value (Phoenix criteria).Results: At a median followup of 38 months, biochemical recurrence free survival was 100%, 89%, and 82.7% at 1, 2, and 3 years, respectively, with overall and cancer specific survival of 100%. The procedure was safe and well tolerated with no major adverse events. All patients were continent at their last followup and 55.2% (16/29) had erectile function sufficient for penetration.Conclusion: Primary zonal HIFU is a valid focal therapy strategy, safe and feasible in day to day practice with good promising results [corrected].","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2014 ","pages":"756189"},"PeriodicalIF":4.2,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3920856/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32168420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Increased aPKC Expression Correlates with Prostatic Adenocarcinoma Gleason Score and Tumor Stage in the Japanese Population. 在日本人群中，aPKC表达增加与前列腺腺癌Gleason评分和肿瘤分期相关

IF 4.2

Prostate Cancer Pub Date : 2014-01-01 Epub Date: 2014-04-29 DOI: 10.1155/2014/481697

Anthony S Perry, Bungo Furusato, Raymond B Nagle, Sourav Ghosh

{"title":"Increased aPKC Expression Correlates with Prostatic Adenocarcinoma Gleason Score and Tumor Stage in the Japanese Population.","authors":"Anthony S Perry, Bungo Furusato, Raymond B Nagle, Sourav Ghosh","doi":"10.1155/2014/481697","DOIUrl":"10.1155/2014/481697","url":null,"abstract":"Background. Levels of the protein kinase aPKC have been previously correlated with prostate cancer prognosis in a British cohort. However, prostate cancer incidence and progression rates, as well as genetic changes in this disease, show strong ethnic variance, particularly in Asian populations. Objective. The aim of this study was to validate association of aPKC expression with prostatic adenocarcinoma stages in a Japanese cohort. Methods. Tissue microarrays consisting of 142 malignant prostate cancer cases and 21 benign prostate tissues were subject to immunohistological staining for aPKC. aPKC staining intensity was scored by three independent pathologists and categorized as absent (0), dim (1+), intermediate (2+), and bright (3+). aPKC staining intensities were correlated with Gleason score and tumor stage. Results. Increased aPKC staining was observed in malignant prostate cancer, in comparison to benign tissue. Additionally, aPKC staining levels correlated with Gleason score and tumor stage. Our results extend the association of aPKC with prostate cancer to a Japanese population and establish the suitability of aPKC as a universal prostate cancer biomarker that performs consistently across ethnicities. ","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2014 ","pages":"481697"},"PeriodicalIF":4.2,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2014/481697","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32374586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Long-term efficacy and tolerability of abdominal once-yearly histrelin acetate subcutaneous implants in patients with advanced prostate cancer. 腹腔注射醋酸组曲林皮下植入物对晚期前列腺癌患者的长期疗效和耐受性。

IF 4.2

Prostate Cancer Pub Date : 2014-01-01 Epub Date: 2014-12-04 DOI: 10.1155/2014/490315

Sean Woolen, Cameron Holzmeyer, Emily Nesbitt, Paul F Siami

{"title":"Long-term efficacy and tolerability of abdominal once-yearly histrelin acetate subcutaneous implants in patients with advanced prostate cancer.","authors":"Sean Woolen, Cameron Holzmeyer, Emily Nesbitt, Paul F Siami","doi":"10.1155/2014/490315","DOIUrl":"10.1155/2014/490315","url":null,"abstract":"Objectives. Long-term assessment of the efficacy and tolerability of subcutaneous abdominal histrelin acetate implants that have been inserted for more than two years. Materials and Methods. Retrospective data collected over a six-year period at a single center from charts of 113 patients who received the subcutaneous abdominal histrelin acetate implant. Results. Following insertion of the first implant, 92.1% and 91.8% of patients had a serum testosterone level of ≤30 ng/dL at 24 and 48 weeks, respectively. Serum testosterone levels remained at <30 ng/dL for 96% of patients at two years and for 100% of patients at 3, 4, and 5 years. The testosterone levels remained significantly less than baseline (P < 0.05). Six patients (5.3%) had androgen-independent progression when followed up on the long term, increasing the mean serum PSA at 3, 4, and 5 years to 35.0 µg/L (n = 22), 30.7 µg/L (n = 13), and 132.9 µg/L (n = 8), respectively. The mean serum PSA was significantly greater than baseline during these years (P < 0.05). Eight patients (7.1%) experienced minor, but not serious, adverse events from the histrelin acetate. Conclusion. Subcutaneous abdominal histrelin acetate implants are an effective long-term and well-tolerated administration method for treating patients with advanced prostate cancer. ","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2014 ","pages":"490315"},"PeriodicalIF":4.2,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4274828/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32940782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Burden of Illness in Prostate Cancer Patients with a Low-to-Moderate Risk of Progression: A One-Year, Pan-European Observational Study. 低至中度进展风险前列腺癌患者的疾病负担:一项为期一年的泛欧观察性研究

IF 4.2

Prostate Cancer Pub Date : 2014-01-01 Epub Date: 2014-03-13 DOI: 10.1155/2014/472949

Cesare Selli, Anders Bjartell, Javier Burgos, Matthew Somerville, Juan-Manuel Palacios, Laure Benjamin, Libby Black, Ramiro Castro

{"title":"Burden of Illness in Prostate Cancer Patients with a Low-to-Moderate Risk of Progression: A One-Year, Pan-European Observational Study.","authors":"Cesare Selli, Anders Bjartell, Javier Burgos, Matthew Somerville, Juan-Manuel Palacios, Laure Benjamin, Libby Black, Ramiro Castro","doi":"10.1155/2014/472949","DOIUrl":"https://doi.org/10.1155/2014/472949","url":null,"abstract":"Objective. To assess the impact of low-to-moderate risk prostate cancer on patients' quality of life (QoL) at diagnosis and within the first year of treatment. Subjects and Methods. Men (n = 672) aged 50-75 years with prostate cancer (Gleason score ≤7, PSA ≤20 ng/mL and clinical staging T1c-T2b) were enrolled in five European countries. Patients completed five questionnaires, including EORTC Quality of Life Questionnaire-Prostate Cancer 25 (QLQ-PR25) and EORTC Quality of Life Questionnaire-Cancer 30 (QLQ-C30). Questionnaires were completed at baseline, at 3 months and 12 months after starting treatment. The primary endpoint was the change in QLQ-PR25 urinary symptoms subscale score from baseline to the assessment at 3 months. Results. Mean (SD) age was 65.0 (5.7) years and 400 (66%) men had Gleason score ≤6 prostate cancer. The most frequently used initial treatment was radical prostatectomy (71% of patients). QLQ-PR25 urinary symptoms subscale score was significantly increased at 3 months (P < 0.001), indicating that urinary symptoms worsened after treatment. The score was lower at 12 months than at 3 months, but it was still significantly higher than at baseline (P < 0.001). Hormonal treatment-related symptoms, sexual functioning, and sexual activity scores significantly worsened at 3 and 12 months (all P < 0.001). For the QLQ-C30 questionnaire, global health status/QoL score significantly decreased at month 3 but was not different from baseline by month 12. Scales for physical, role, and social functioning, and fatigue, showed significant deterioration at 3 and 12 months. Conclusions. Low-to-moderate risk prostate cancer may have a substantial effect on patients' QoL within one year following treatment. ","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2014 ","pages":"472949"},"PeriodicalIF":4.2,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2014/472949","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32285147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 20